Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Nicole Lamanna, John M. Pagel, Ian W. Flinn, Jacqueline C. Barrientos, Kanti R. Rai, James A. Reeves, Bruce D. Cheson, Paul M. Barr, Suman Kambhampati, Frederick Lansigan, Jeffrey J. Pu, Alan P. Skarbnik, Lindsey Roeker, Gustavo A. Fonseca, Andrea Sitlinger, Issam S. Hamadeh, Colleen DorseyNicole LaRatta, Hanna Weissbrot, Eline T. Luning Prak, Patricia Tsao, Dana Paskalis, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Jakub Svoboda, Danielle M. Brander

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds